Most recent update: Monday, July 15, 2019 - 08:50

Bariatric News - Cookies & privacy policy

You are here

diabetes

New US diabetes cases fall as obesity rises

The number of new diabetes cases among US adults keeps falling, even as obesity rates climb, according to research led by Dr Stephen Benoit of the Centers for Disease Control and Prevention. The new federal data revealed the number of new diabetes diagnoses fell to about 1.3 million in 2017, down from 1.7 million in 2009, a decline that has been going on for close to a decade. However, health officials are not celebrating.

ZGN-1061 trial shows clinically significant 1.1% reduction of A1C

Zafgen has announced positive data for the second cohort of its Phase 2 clinical trial of ZGN-1061, designed to evaluate efficacy and safety in patients with type 2 diabetes and the likely therapeutic dose range of ZGN-1061 up to 1.8mg. The clinical trial met all of its primary objectives at the 1.8mg dose, which included glycaemic control or change in A1C, and safety and tolerability.

Very low-calorie diets trialled by NHS to tackle diabetes

Hundreds of thousands of people in the England will receive NHS help to battle obesity and type 2 diabetes in a programme that will not only improve the health of patients but also save the NHS money that can be reinvested in frontline care. Currently, the health service in England spends around 10 percent of its budget on treating diabetes.

Alcohol intake and long-term weight loss for diabetics

A study from the University of Pennsylvania School of Nursing (Penn Nursing) suggests that alcohol consumption may attenuate long-term weight loss in adults with Type 2 diabetes. Although research shows that losing weight can help prevent or delay the onset of diabetes and achieving this often includes decreasing or eliminating calories from alcohol, few studies examine whether people who undergo weight loss treatment report changes in alcohol intake and whether alcohol influences their weight loss.

Bariatric surgery reduces coronary heart disease risk by 40 percent

Patients with severe obesity who get weight-loss surgery cut their risk of developing coronary heart disease by about 40 percent, according to a new study from Cleveland Clinic Florida researchers who presented their findings at ObesityWeek 2018, hosted by the American Society for Metabolic and Bariatric Surgery (ASMBS) and The Obesity Society (TOS).

Metabolic surgery reduces mortality from diabetes or any other cause

People with diabetes and severe obesity who had metabolic surgery were much less likely to die from diabetes or any other cause than those who received drug therapy alone, according to a meta-analysis by German researchers who presented their findings at ObesityWeek 2018, hosted by the American Society for Metabolic and Bariatric Surgery (ASMBS)and The Obesity Society (TOS).

Genetics associated with obesity may protect against diabetes

Some genetic variations associated with obesity actually protect against Type 2 diabetes, heart attack and stroke, according to researchers from Brunel University London and the University of Exeter, UK. It is believed that genetics may determine where on the body people store surplus fat, whether round their middle or round the liver. Crucially, where extra fat is stored matters more than the amount when it comes to insulin resistance and risk of diabetes and other conditions. The paper.

Gene mutation slows metabolism lowering diabetes and obesity risk

Researchers at Harvard Medical School and Brigham and Women's Hospital have discovered a gene mutation that slows the metabolism of sugar in the gut, giving people who have the mutation a distinct advantage over those who do not. Those with the mutation have a lower risk of diabetes, obesity, heart failure, and even death. The researchers claim that their findings could provide the basis for drug therapies that could mimic the workings of this gene mutation, offering a potential benefit for the millions of people who suffer with diabetes, heart disease and obesity.

Weight loss drug lorcaserin has positive effect on diabetes

Investigators from the Thrombolysis in Myocardial Infarction (TIMI) Study Group have reported that lorcaserin (Belviq), a weight loss drug manufactured by Eisai who is sponsoring the CAMELLIA-TIMI 61 clinical trial, demonstrated sustained weight loss without an increased risk of major cardiovascular events (MACE). The diabetes-related findings from CAMELLIA-TIMI 61, a clinical trial of overweight and obese patients designed to test lorcaserin, were presented at the 2018 Meeting of the European Association for the Study of Diabetes by researchers from the Brigham and Women's Hospital.

Improved glycaemic control with Tresiba vs Glargine U100

According to results of a post-hoc analysis people with both type 1 and type 2 diabetes in clinical practice may achieve improved glycaemic control (HbA1c) with Tresiba (insulin degludec) versus insulin glargine U100, without an increase in hypoglycaemia (potentially dangerous low blood sugar) (1). The results of this new analysis from the SWITCH 1 and 2 trials were presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD 2018) in Berlin, Germany.

Subscribe to RSS - diabetes